Dare Bioscience Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
DARE Nasdaq 8731 https://www.darebioscience.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dare Bioscience Inc

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 - Sep 21st, 2023 12:00 pm
Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting - Sep 20th, 2023 12:00 pm
Daré Bioscience to Participate in Upcoming Investor Conferences - Sep 6th, 2023 12:00 pm
Daré Bioscience Completes Previously Announced Equity Financing - Sep 5th, 2023 12:00 pm
Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Aug 30th, 2023 12:00 pm
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2023 Earnings Call Transcript - Aug 12th, 2023 1:35 pm
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates - Aug 10th, 2023 1:30 pm
Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update - Aug 10th, 2023 12:00 pm
Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings - Aug 9th, 2023 12:00 pm
Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023 - Aug 3rd, 2023 12:00 pm
Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth - Jul 31st, 2023 12:00 pm
Investors in Daré Bioscience (NASDAQ:DARE) have unfortunately lost 33% over the last five years - Jul 29th, 2023 12:53 pm
Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems - Jul 11th, 2023 9:30 pm
Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women - Jul 11th, 2023 12:00 pm
Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder - Jul 6th, 2023 12:00 pm
Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis - Jul 5th, 2023 12:00 pm
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women - Jun 21st, 2023 12:00 pm
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully - Jun 18th, 2023 1:55 pm
Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference - Jun 14th, 2023 12:00 pm
Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, the Journal of the International Menopause Society - Jun 9th, 2023 12:00 pm